Beta2-adrenergic agonist

{{Short description|Compounds that bind to and activate adrenergic beta-2 receptors}}

{{DISPLAYTITLE:Beta2-adrenergic agonist}}

{{More citations needed|date=December 2008}}

{{Use dmy dates|date=February 2020}}

File:Salbutamol.svg (albuterol) — an example of β2 agonist]]

Beta2-adrenergic agonists, also known as adrenergic β2 receptor agonists, are a class of drugs that act on the β2 adrenergic receptor. Like other β adrenergic agonists, they cause smooth muscle relaxation. β2 adrenergic agonists' effects on smooth muscle cause dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin. They are primarily used to treat asthma and other pulmonary disorders. Bronchodilators are considered an important treatment regime for chronic obstructive pulmonary disease (COPD) and are usually used in combination with short acting medications and long acting medications in a combined inhaler.{{cite book | vauthors = Hsu E, Bajaj T | chapter = Beta 2 Agonists | title = StatPearls | location = Treasure Island (FL) | publisher = StatPearls Publishing | year = 2022 | pmid = 31194406 | chapter-url = https://www.ncbi.nlm.nih.gov/books/NBK542249/ | access-date = 2022-04-05 | via = NCBI }}{{Cite journal |last=van Geffen |first=Wouter H. |last2=Tan |first2=Daniel J. |last3=Walters |first3=Julia Ae |last4=Walters |first4=E. Haydn |date=2023-12-06 |title=Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease |url=https://pubmed.ncbi.nlm.nih.gov/38054551 |journal=The Cochrane Database of Systematic Reviews |volume=12 |issue=12 |pages=CD011600 |doi=10.1002/14651858.CD011600.pub3 |issn=1469-493X |pmc=10698842 |pmid=38054551}}

Mechanism of action

{{unreferenced section|date=February 2020}}

Activation of β adrenergic receptors leads to relaxation of smooth muscle in the lung, and dilation and opening of the airways.{{cite journal | vauthors = Proskocil BJ, Fryer AD | title = Beta2-agonist and anticholinergic drugs in the treatment of lung disease | journal = Proceedings of the American Thoracic Society | volume = 2 | issue = 4 | pages = 305–310 | date = 2005-11-01 | pmid = 16267353 | doi = 10.1513/pats.200504-038SR | s2cid = 22198277 }}

β adrenergic receptors are coupled to a stimulatory G protein of adenylyl cyclase. This enzyme produces the second messenger cyclic adenosine monophosphate (cAMP). In the lung, cAMP decreases calcium concentrations within cells and activates protein kinase A. Both of these changes inactivate myosin light-chain kinase and activate myosin light-chain phosphatase. In addition, β2 agonists open large conductance calcium-activated potassium channels and thereby tend to hyperpolarize airway smooth muscle cells. The combination of decreased intracellular calcium, increased membrane potassium conductance, and decreased myosin light chain kinase activity leads to smooth muscle relaxation and bronchodilation.

Adverse effects

Findings indicate that β2 stimulants, especially in parenteral administration such as inhalation or injection, can induce adverse effects:

  • Tachycardia secondary to peripheral vasodilation and cardiac stimulation (such tachycardia may be accompanied by palpitations).{{cite book | vauthors = Almadhoun K, Sharma S | chapter = Bronchodilators |date=2020 | chapter-url = http://www.ncbi.nlm.nih.gov/books/NBK519028/ | title = StatPearls|publisher=StatPearls Publishing|pmid=30085570|access-date=2020-03-16 }}
  • Tremor, excessive sweating, anxiety, insomnia, and agitation{{cite journal | vauthors = Billington CK, Penn RB, Hall IP | title = β2 Agonists | journal = Handbook of Experimental Pharmacology | volume = 237 | pages = 23–40 | year = 2016 | pmid = 27878470 | pmc = 5480238 | doi = 10.1007/164_2016_64 | isbn = 978-3-319-52173-2 }}
  • More severe effects include paradoxical bronchospasm, hypokalemia, and in rare cases a myocardial infarction. (More severe effects, such as pulmonary edema, myocardial ischemia, and cardiac arrhythmia, are exceptional.){{cite journal | vauthors = Lulich KM, Goldie RG, Ryan G, Paterson JW | title = Adverse reactions to beta 2-agonist bronchodilators | journal = Medical Toxicology | volume = 1 | issue = 4 | pages = 286–299 | date = July 1986 | pmid = 2878344 | doi = 10.1007/bf03259844 | s2cid = 58394547 }}{{Cite book | vauthors = McCoshen JA, Fernandes PA, Boroditsky ML, Allardice JG | chapter=Determinants of Reproductive Mortality and Preterm Childbirth |date= January 1996 | veditors = Bittar EE, Zakar T | title = Advances in Organ Biology |pages=195–223 |publisher=Elsevier|language=en| volume = 1: Pregnancy and Parturition |doi=10.1016/S1569-2590(08)60073-7 |isbn=978-1-55938-639-5 }}

Overuse of β2 agonists and asthma treatment without proper inhaled corticosteroid use has been associated with an increased risk of asthma exacerbations and asthma-related hospitalizations.{{cite journal | vauthors = Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP | display-authors = 6 | title = Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes | journal = The European Respiratory Journal | volume = 59 | issue = 1 | pages = 2102730 | date = January 2022 | pmid = 34667060 | pmc = 8719459 | doi = 10.1183/13993003.02730-2021 }} The excipients, in particular sulfite, could contribute to the adverse effects.

Delivery

{{unreferenced section|date=February 2020}}

All β2 agonists are available in inhaler form, as either metered-dose inhalers which dispense an aerosolized drug and contains propellants, dry powder inhalers which dispense a powder to be inhaled, or soft mist inhalers which dispense a mist without use of propellants.{{cite journal | vauthors = Sorino C, Negri S, Spanevello A, Visca D, Scichilone N | title = Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler | language = English | journal = European Journal of Internal Medicine | volume = 75 | pages = 15–18 | date = May 2020 | pmid = 32113944 | doi = 10.1016/j.ejim.2020.02.023 | s2cid = 211727980 }}

Salbutamol (INN) or albuterol (USAN) and some other β2 agonists, such as formoterol, also are sold in a solution form for nebulization, which is more commonly used than inhalers in emergency rooms. Nebulizers continuously deliver aerosolized drug and salbutamol delivered through nebulizer was found to be more effective than IV administration.{{cite encyclopedia | vauthors = Gad SE | chapter = Albuterol |date=2014 | chapter-url=https://linkinghub.elsevier.com/retrieve/pii/B9780123864543008095 |encyclopedia=Encyclopedia of Toxicology |pages=112–115 |access-date=2023-04-24 |publisher=Elsevier |language=en |doi=10.1016/b978-0-12-386454-3.00809-5 |isbn=978-0-12-386455-0}}

Salbutamol and terbutaline are also both available in oral forms.{{Cite book |title=Paediatric Cardiology |year=2010 |pages=199–218 |chapter-url=https://www.sciencedirect.com/science/article/pii/B9780702030642000126 |chapter=CHAPTER 12 - Pharmacological and Interventional Fetal Cardiovascular Treatment|doi=10.1016/B978-0-7020-3064-2.00012-6 |edition=Third | vauthors = Jaeggi ET, Tulzer G |publisher=Churchill Livingstone |isbn=978-0-7020-3064-2 }} In addition, several of these medications are available in intravenous forms, including both salbutamol and terbutaline. It can be used in this form in severe cases of asthma, but it is more commonly used to suppress premature labor because it also relaxes uterine muscle, thereby inhibiting contractions.{{cite journal | vauthors = Motazedian S, Ghaffarpasand F, Mojtahedi K, Asadi N | title = Terbutaline versus salbutamol for suppression of preterm labor: a randomized clinical trial | journal = Annals of Saudi Medicine | volume = 30 | issue = 5 | pages = 370–375 | date = 2010 | pmid = 20697169 | pmc = 2941249 | doi = 10.4103/0256-4947.67079 | doi-access = free }}

Risks

On 18 November 2005, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing in some people, and requested that manufacturers update warnings in their existing product labeling.{{medcn|date=February 2020}}

A 2006 meta-analysis found that "regularly inhaled β agonists (orciprenaline/metaproterenol [Alupent], formoterol [Foradil], fluticasone+salmeterol [Serevent, Advair], and salbutamol/albuterol [Proventil, Ventolin, Volmax, and others]) increased the risk of respiratory death more than two-fold, compared with a placebo," while{{vague|reason= During use? Despite being prescribed? such vagueness by a physician might constitute malpractice!|date=August 2020}} used to treat chronic obstructive pulmonary disease.{{cite journal | vauthors = Salpeter SR, Buckley NS, Salpeter EE | title = Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD | journal = Journal of General Internal Medicine | volume = 21 | issue = 10 | pages = 1011–1019 | date = October 2006 | pmid = 16970553 | pmc = 1831628 | doi = 10.1111/j.1525-1497.2006.00507.x }}

  • {{lay source |template = cite news|vauthors = Ramanujan K |url = https://news.cornell.edu/stories/2006/06/beta-agonist-inhalers-more-double-death-rate-copd-patients |title= Common beta-agonist inhalers more than double death rate in COPD patients, Cornell and Stanford scientists assert |date = June 29, 2006 |website = Cornell Chronicle }}

On 11 December 2008, a panel of experts convened by the FDA voted to ban{{vague|reason = to legally impose the ban , to advise some official with that power to do so? Traditionally, the term refers to social and/or physical expulsion of a person; here, a link to a (US-)applicable legal topic is called for|date=August 2020}} drugs Serevent and Foradil from use in the treatment of asthma. When these two drugs are used without steroids, they increase the risks of more severe attacks. They said that two other, much more popular, asthma drugs containing long-acting β agonists—Advair and Symbicort—should continue to be used.{{cite news |url=https://www.nytimes.com/2008/12/12/health/policy/12fda.html |title=F.D.A. Panel Votes to Ban Asthma Drugs | vauthors = Harris G |date=11 December 2008 |website=The New York Times |access-date=19 January 2009 }}

Types

= Short-acting β<sub>2</sub> agonists (SABAs) =

= Long-acting β<sub>2</sub> agonists (LABAs) =

  • arformoterol—Brovana (some consider it to be an ultra-LABA){{cite journal | vauthors = Matera MG, Cazzola M | title = ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? | journal = Drugs | volume = 67 | issue = 4 | pages = 503–515 | date = 2007 | pmid = 17352511 | doi = 10.2165/00003495-200767040-00002 | s2cid = 46976912 }}
  • bambuterol—Bambec, Oxeol
  • clenbuterol—Dilaterol, Spiropent
  • formoterol—Foradil, Oxis, Perforomist
  • salmeterol—Serevent

= Ultra-long-acting β<sub>2</sub> agonists =

{{cite journal | vauthors = Cazzola M, Matera MG, Lötvall J | title = Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease | journal = Expert Opinion on Investigational Drugs | volume = 14 | issue = 7 | pages = 775–783 | date = July 2005 | pmid = 16022567 | doi = 10.1517/13543784.14.7.775 | s2cid = 11930383 }}{{cite journal | vauthors = Cazzola M, Calzetta L, Matera MG | title = β(2) -adrenoceptor agonists: current and future direction | journal = British Journal of Pharmacology | volume = 163 | issue = 1 | pages = 4–17 | date = May 2011 | pmid = 21232045 | pmc = 3085864 | doi = 10.1111/j.1476-5381.2011.01216.x | doi-access = free }}

= Unknown duration of action =

Research

New drugs in this class with more selective activity or that act simultaneously as muscarinic receptor antagonists are under development as of 2023.{{cite journal | vauthors = Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M | title = Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update | journal = Expert Opinion on Pharmacotherapy | pages = 1–10 | date = November 2023 | pmid = 37955136 | doi = 10.1080/14656566.2023.2282673 | s2cid = 265148154 }}

Society and culture

β2 agonists are used by athletes and bodybuilders as anabolic performance-enhancing drugs and their use has been banned by the World Anti-Doping Agency except for certain drugs that people with asthma may use; they are also used illegally to try to promote the growth of livestock.{{cite web | work = Drug Enforcement Administration | date = November 2013 | url = http://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf | title= Clenbuterol | archive-url = https://web.archive.org/web/20191017084433/https://www.deadiversion.usdoj.gov/drug_chem_info/clenbuterol.pdf | archive-date=17 October 2019 }} A 2011 meta-analysis found no evidence that inhaled β₂-agonists improve performance in healthy athletes and found that the evidence was too weak to assess whether systemic administration of β₂-agonists improved performance in healthy people.{{cite journal | vauthors = Pluim BM, de Hon O, Staal JB, Limpens J, Kuipers H, Overbeek SE, Zwinderman AH, Scholten RJ | display-authors = 6 | title = β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials | journal = Sports Medicine | volume = 41 | issue = 1 | pages = 39–57 | date = January 2011 | pmid = 21142283 | doi = 10.2165/11537540-000000000-00000 | s2cid = 189906919 }}

See also

References

{{reflist}}